Tse 2372
2372.TTSE PRIME
Filed as I'rom Group Co., Ltd. (2022-06–2024-11)
Financials · Consolidated
| Fiscal year ended | 2024-03 | 2023-03 | 2022-03 | 2021-03 | 2020-03 | 2019-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥17.7bn | ¥18.4bn | ¥15.7bn | ¥12.9bn | ¥10.6bn | ¥10.6bn |
| Operating income | ¥1.1bn | ¥3.6bn | ¥2.8bn | ¥1.1bn | — | — |
| Ordinary income | ¥1.8bn | ¥3.3bn | ¥2.6bn | ¥1.4bn | ¥1.1bn | ¥1.2bn |
| Net income (owners) | ¥1.4bn | ¥2.5bn | ¥2.0bn | ¥1.4bn | ¥1.2bn | ¥912m |
| Total assets | ¥37.1bn | ¥35.1bn | ¥26.6bn | ¥20.9bn | ¥15.1bn | ¥13.5bn |
| Net assets / equity | ¥12.8bn | ¥12.2bn | ¥10.2bn | ¥8.7bn | ¥7.2bn | ¥6.1bn |
| Operating cash flow | ¥446m | ¥3.6bn | ¥2.6bn | ¥374m | ¥637m | ¥504m |
| EPS (basic) | ¥116.92 | ¥210.22 | ¥162.5 | ¥114.3 | ¥105.82 | ¥78.31 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2024-04-01 → 2024-09-30 | Half-year | 69 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2024-03
| Segment | External sales | Profit |
|---|---|---|
| Advanced Medical | ¥1.5bn | −¥133m |
| CRO | ¥6.4bn | ¥489m |
| Drug Discovery Business | — | −¥601m |
| Medical Support | ¥1.1bn | ¥66m |
| SMO | ¥8.7bn | ¥3.5bn |
| Other segments | ¥25m | −¥256m |
| Adjustments & eliminations | — | −¥1.9bn |
| Total | ¥17.7bn | ¥3.3bn |
| Total | ¥17.7bn | ¥3.1bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.